Floatz logo

cd5-targeted car-t cells

PTCL

Peking University People's HospitalCell therapyPhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

135 Active assets in the PTCL cohort.

Asset / SponsorPhaseRating
Inno-206
BeBetter Med Inc
Phase 4BBB
Pralatrexate
Peking University People's Hospital
Phase 4BBB
PREDNISONE TABLETS
Tarapeutics Science Inc.
Phase 4BBB
Cyclophosphamide
Tarapeutics Science Inc.
Phase 4BBB
(+)-VINCRISTINE
BeBetter Med Inc
Phase 4BBB

View all 50 →

Same molecule, other indications

cd5-targeted car-t cells is also rated in:

T-cell non-Hodgkin lymphomaDormant
CCC
Indicative ·
54 / 100
View asset →
T-cell acute lymphoblastic leukemiaDormant
CCC
Indicative ·
50 / 100
View asset →
precursor T-cell acute lymphoblastic leukemiaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →